Crosstalk and Convergence in Alzheimer's Disease: Integrating Brain Injury, Neuroinflammation, and Precision Medicine for Next-Generation Therapeutics.
This review proposes conceptualizing Alzheimer's disease as a neural circuit disorder that emerges from sustained crosstalk among multiple interacting pathways, including brain injury, neuroinflammation, mitochondrial and metabolic dysfunction, neurovascular dysfunction, neurovascular dysfunction, synaptic dysfunction, and individual vulnerability.
Abstract
Alzheimer's Disease (AD) is a complex disorder whose underlying biology is not fully explained by traditional single-pathway models. For several decades, research has largely focused on the roles of amyloid-β and tau in the formation and deposition of plaques and neurofibrillary tangles associated with AD pathology and neurodegeneration. Despite this sustained focus, therapeutic strategies targeting amyloid-β and tau alone have shown limited success in altering the natural course of the disease. Accordingly, there is a clear need for an adaptive and integrative framework that better captures the heterogeneity and dynamic nature of disease progression over time. This review proposes conceptualizing Alzheimer's disease as a neural circuit disorder that emerges from sustained crosstalk among multiple interacting pathways, including brain injury, neuroinflammation, mitochondrial and metabolic dysfunction, neurovascular dysfunction (impaired supply chain), synaptic dysfunction, and individual vulnerability. Evidence is presented to illustrate (1) how the traumatic and chronic nature of brain injury predisposes the brain to persistent inflammation and neurodegeneration; (2) how astrocytic and microglial activation states contribute to synaptic dysfunction and neuronal damage; and (3) how pathological interactions among amyloid pathology, tau dysregulation, and immune signaling collectively exacerbate neuroinflammatory responses and accelerate disease progression in AD.
Overall, this review makes a case for integrative, pathway-based therapeutic models, and multiple approaches may facilitate for drug development, biomarker identification and patient management in Alzheimer's disease.
A “cellular state–pathological network–therapeutic window” framework is proposed and the roles of microglia in amyloid-β plaque seeding and compaction, NLRP3 inflammasome activation, mitochondrial DNA–cGAS–STING signaling, complement-mediated synaptic engulfment, and bidirectional microglia–tau feedback are systematica...
Lian-Jing Xu, Ying Zhang, Li Jiang et al.· Frontiers in Cellular Neuros...· 0 citations
Evidence supports a shift from a linear amyloid model to a multidimensional framework and offers promise for early detection, risk stratification, and personalized multi-target therapies in AD.
C. D. Souza, Shiva Murthy Nanjundappa, N. Murali· International Journal of Bas...· 0 citations
This review examines the molecular and cellular mechanisms through which neuroinflammation contributes to the progression of AD, with particular emphasis on microglial activation, TREM2 and soluble TREM2 (sTREM2) signaling, NLRP3 inflammasome activation, astrocyte–microglia interactions, and blood–brain barrier dysfunc...
Shreyansh Goswami· International Journal For Mu...· 0 citations
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder that affects millions of people worldwide and poses a major global health challenge. This complex disease involves multiple pathogenic factors, including amyloid-beta (Aβ), tau protein aggregation, synaptic dysfunction, mitochondrial impairment, oxida...
Mona Piplani, Shivani Thakur, Pankaj Kumar et al.· Biomedical & Pharmacolog...· 0 citations
Alzheimer’s disease (AD) is the leading cause of dementia and a heterogeneous neurodegenerative disorder characterized by amyloid-β (Aβ) and tau pathology, impaired proteostasis, neurovascular dysfunction, maladaptive glial and immune responses, and synaptic dysfunction. Human genetic evidence supports an upstream role...
P. Chmielewski· Cells· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.